G&S Capital’s Novartis NVS Stock Holding History

G&S Capital’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-105	Closed	-$8K	–	152
2020 Q1	$8K	Sell	105 -42,463	-100%	-$3.79M	0.01%	139
2019 Q4	$4.03M	Sell	42,568 -350	-0.8%	-$31.4K	2.27%	16
2019 Q3	$3.73M	Buy	42,918 +2,596	+6%	+$233K	2.17%	19
2019 Q2	$3.68M	Buy	40,322 +19,319	+92%	+$1.64M	2.21%	17
2019 Q1	$1.81M	Buy	21,003 +20,893	+18,994%	+$1.68M	1.11%	27
2018 Q4	$8K	Buy	+110	New	+$8.56K	0.01%	160

Other funds holding NVS

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mawer Investment Management Calgary, Alberta, Canada $15.4B AUM 10.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

G&S Capital's NVS Position: Q2 2020 in Review

G&S Capital sold out of Novartis (NVS) in Q2 2020, closing a stake of 105 shares — an estimated $8K sold.

G&S Capital first reported a position in NVS in Q4 2018 and held it in 6 quarters. The position peaked at $4.03M in Q4 2019. 1,128 funds tracked by Wall St. Rank hold NVS as of Q2 2020.

G&S Capital reported no remaining Novartis position as of Q2 2020 after selling out during the quarter.
G&S Capital sold 105 Novartis shares in Q2 2020, an estimated $8K.
G&S Capital first reported a position in Novartis in Q4 2018 and held it in 6 quarters.
G&S Capital's Novartis position peaked at $4.03M in Q4 2019.
1,128 funds tracked by Wall St. Rank held Novartis as of Q2 2020.

Based on G&S Capital's 13F filing for Q2 2020, filed 24 Jul 2020.